About chronic pain
Currently, more than 1.5 billion people worldwide suffer from chronic pain of varying degrees. Among all types of chronic pain, neuropathic pain stands out with approximately 3-4.5% of the global population affected, with incidence rate increasing in line with increased age of the population. With the unmet clinical need so high, the demand for better pain management therapies, addressing acute and chronic pain, is on the rise.
According to recent research the global pain management market is to reach
- Global Industry Analysts Inc. 2010, "Pain Management: A Global Strategic Business Report".
About Convergence Pharmaceuticals
Convergence Pharmaceuticals is an independent biotechnology company focused on the development of novel analgesics with potentially commercially attractive efficacy, responder-rate and side effect profiles. The Company, led by CEO
, was formed in
following the acquisition of certain neuroscience clinical assets from GlaxoSmithKline ("GSK"). The Company has a pipeline of differentiated clinical-stage compounds targeting the points of convergence in chronic pain signalling through modulation of specific ion-channels.
Convergence Pharmaceuticals is well funded and raised
in Series A financing from a syndicate of leading European and US financial institutions. For more information please go to the Company's website at
As part of a restructuring of Convergence in 2011, CNV2197944 was subsequently transferred into Calchan Ltd. Calchan Ltd is developing its own portfolio of Calcium ion channel modulators and has contracted Convergence to undertake certain development activities with CNV2197944 on its behalf.
For more information about Convergence Pharmaceuticals, please contact:
, Chief Executive Officer Dr
, Chief Scientific Officer T: +44-(0)1223-755-501 E:
T: +44-(0)20-7920-2361 E:
SOURCE Convergence Pharmaceuticals Ltd